Premium
Follow‐up of patients treated by prostaglandins eyedrops. Preliminary results from the FREE survey
Author(s) -
GrabskaLiberek I.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0571
Subject(s) - latanoprost , medicine , tolerability , glaucoma , secondary glaucoma , ophthalmology , prospective cohort study , ocular hypertension , adverse effect , surgery
Purpose After lack of efficacy, local intolerance is the second reason to change glaucoma treatment. It was demonstrated that preservatives alter the local tolerability. With the newly available preservative‐free (PF) prostaglandins and the launch of a PF latanoprost (Monoprost ® ), it is interesting to assess the evolution of ocular signs and symptoms after switch from preserved to PF glaucoma treatment. This was the objective of the FREE survey (Follow‐up of glaucoma patients treated with Prostaglandins EyEdrops). Methods FREE is a prospective, European, multicentre, prospective survey implemented in ophthalmological private practices in France, the Netherlands, Norway, Poland and Sweden. The study is still ongoing to recruit a total of 1400 patients. Three study visits (inclusion and two visits after 6 and 12 months) are planned. Hyperemia and patient's satisfaction with regards to tolerance are the main evaluation criteria. Other parameters are recorded: patient feeling assessment on tolerance to the current glaucoma treatment, the ocular surface diseases, the use of tear substitutes, the ocular signs, fluorescein corneal and conjunctival stainings and tear BUT. Results The first results from the five countries will be presented here for the first time. From the first analysis of 588 patients (354 in France, 96 in Poland, 79 in Sweden, 35 in the Netherlands and 24 in Norway), clinical signs appeared to be more present with preserved eyedrops than with PF treatment and especially with PF latanoprost at the subsequent visits. The results with PF latanoprost (Monoprost ® ) on long term (superior to 6 months) will be presented here for the first time. Conclusions This preliminary first results of FREE survey confirm the clinical interest of switching from a preserved to a PF prostaglandin for a better treatment tolerability and patient satisfaction.